Compare · DFTX vs SUPN
DFTX vs SUPN
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Supernus Inc. (SUPN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. DFTX focuses on Medicinal Chemicals and Botanical Products, while SUPN focuses on Biotechnology: Pharmaceutical Preparations.
- SUPN is the larger of the two at $5.94B, about 1.5x DFTX ($3.88B).
- Over the past year, DFTX is up 141.1% and SUPN is down 13.1% - DFTX leads by 154.3 points.
- SUPN has been more active in the news (31 items in the past 4 weeks vs 9 for DFTX).
- SUPN has more recent analyst coverage (10 ratings vs 8 for DFTX).
- Company
- Definium Therapeutics Inc.
- Supernus Inc.
- Price
- -
- -
- Market cap
- $3.88B
- $5.94B
- 1M return
- -21.27%
- -18.95%
- 1Y return
- +141.13%
- -13.13%
- Industry
- Medicinal Chemicals and Botanical Products
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2012
- News (4w)
- 9
- 31
- Recent ratings
- 8
- 10
Supernus Inc.
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. Its commercial products include Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise APOKYN, a product indicated for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO, a product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults. In addition, its product candidates include SPN-812, which has completed Phase III clinical trials that is used for the treatment of attention deficit hyperactivity disorder (ADHD); SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; and SPN-820, a novel product candidate in Phase I clinical trials for treatment resistant depression. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development and option agreement with Navitor Pharmaceuticals, Inc. to conduct a Phase II clinical program for NV-5138 in treatment-resistant depression. The company was founded in 2005 and is headquartered in Rockville, Maryland.
Latest DFTX
- SEC Form SCHEDULE 13G filed by Definium Therapeutics Inc.
- SEC Form SCHEDULE 13G filed by Definium Therapeutics Inc.
- SEC Form 10-Q filed by Definium Therapeutics Inc.
- Definium Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
- Definium Therapeutics Announces New Employee Inducement Grants
- SEC Form SCHEDULE 13G filed by Definium Therapeutics Inc.
- Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress
- Definium Therapeutics to Participate at Upcoming Investor Conferences
- Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026
Latest SUPN
- Wells Fargo initiated coverage on Supernus Pharma with a new price target
- Supernus, Inc. to Participate in the 2026 Jefferies Global Healthcare Conference in London
- BofA Securities initiated coverage on Supernus Pharma with a new price target
- Director Gemayel Georges disposed of 27,277 shares, closing all direct ownership in the company (SEC Form 4)
- SVP, Commercial Operations Horich William Todd disposed of 115,125 restricted stock units, disposed of 8,500 performance share units and disposed of 140,500 employee stock options (SEC Form 4)
- President, CEO Khattar Jack A. disposed of 2,216,451 shares, closing all direct ownership in the company (SEC Form 4)
- Senior Vice-President & CFO Dec Timothy C disposed of 9,129 shares, closing all direct ownership in the company (SEC Form 4)
- Director Barlow Carrolee disposed of 27,045 shares, closing all direct ownership in the company (SEC Form 4)
- Sr. VP of IP, CSO Bhatt Padmanabh P. disposed of 18,637 shares, closing all direct ownership in the company (SEC Form 4)
- SVP, Chief Medical Officer Rubin Jonathan disposed of 13,979 shares, closing all direct ownership in the company (SEC Form 4)